Maternal antiepileptic drug exposure and congenital malformations
Epilepsy during pregnancy presents a difficult balance between controlling maternal seizures and limiting fetal exposure to medication. Generalized convulsive seizures can cause trauma, hypoxia, and other serious complications, so stopping treatment abruptly may place both pregnant patient and fetus at risk. At the same time, several antiseizure medicines are associated with an increased likelihood of major congenital anomalies.
The relationship is complex rather than uniform. Risk depends on the specific antiepileptic drug, daily dose, number of medicines used, genetic susceptibility, folate status, and the timing of exposure during embryonic development. The underlying epilepsy and related health conditions may also influence pregnancy outcomes.
Research in perinatal and neonatal medicine has therefore focused on identifying safer treatment patterns without compromising seizure control. The FAOPS 2020 congress site provides historical context for the scientific community studying fetal development, neonatal outcomes, and pregnancy-related clinical care in Asia and Oceania.
How fetal exposure affects development
Organ formation occurs primarily during the first trimester, often before pregnancy is recognized. Drug exposure during this period can interfere with cell signaling, folate-dependent pathways, vascular development, or tissue differentiation. The resulting abnormalities may involve the heart, neural tube, face, limbs, urinary system, or other organs.
A congenital malformation is a structural difference present at birth. Major congenital anomalies generally require medical treatment, surgery, or have substantial effects on function. Some antiseizure medicines have also been associated with fetal growth restriction, developmental concerns, or altered neurodevelopment, which are separate outcomes from structural birth defects but important when evaluating overall pregnancy safety.
Risk estimates must be interpreted against the background rate in the general population. Every pregnancy has a baseline possibility of a major birth defect, commonly estimated at approximately 2% to 3%. Medication exposure may increase that probability, but an increased relative risk does not mean that an affected pregnancy is inevitable.
Medicines with different risk profiles
Valproate has the clearest and most consistent association with dose-related teratogenicity among commonly used antiseizure medicines. First-trimester exposure has been linked with neural tube defects, cardiac abnormalities, facial differences, limb anomalies, and other major malformations. Higher doses and combination therapy generally carry greater concern. Prenatal valproate exposure has also been associated with later cognitive and developmental effects.
Carbamazepine is associated with a lower overall malformation risk than valproate, although neural tube defects and other abnormalities have been reported. Its risk can rise with increasing dose and concurrent use of other antiepileptic drugs. Phenobarbital and topiramate also warrant careful review because studies have identified associations with selected congenital anomalies, including oral clefts or impaired fetal growth in some exposure settings.
Lamotrigine and levetiracetam are often considered among the options with more reassuring pregnancy safety data, particularly when used as monotherapy at the lowest effective dose. Available evidence does not make them risk-free, and findings can vary between registries and populations. The absence of a strong signal is encouraging, but it should not be interpreted as proof that fetal exposure has no consequences.
| Antiseizure medicine or pattern | Findings commonly reported in pregnancy studies | Practical interpretation |
|---|---|---|
| Valproate | Higher risk of major congenital anomalies, with dose-related effects and neurodevelopmental concerns | Avoid when clinically feasible, especially during early pregnancy |
| Carbamazepine | Increased risk above baseline, including neural tube defects; risk may rise with dose or polytherapy | Requires individualized assessment and prenatal planning |
| Phenobarbital | Associations with major malformations and possible fetal growth concerns | Review alternatives when seizure control allows |
| Topiramate | Increased risk of oral clefts and fetal growth restriction in some studies | Use only when benefits clearly justify exposure |
| Lamotrigine | Generally lower malformation risk than valproate; levels may change during pregnancy | Monitor clinical response and adjust carefully |
| Levetiracetam | Relatively reassuring registry findings, though evidence continues to develop | Often considered when suitable for the seizure type |
| Multiple-drug therapy | Higher observed risk than many single-drug regimens | Simplify treatment only if seizure control can be maintained |
These comparisons describe population-level evidence, not a prescription rule. A medicine that appears safer in one study may be less effective for a particular seizure type, and uncontrolled seizures can themselves threaten maternal and fetal health.
Why dose and polytherapy matter
The relationship between medication dose and malformation risk is especially important for valproate, carbamazepine, and some other agents. Blood concentrations, metabolism, adherence, and changes in body weight can alter exposure during pregnancy. A dose that was adequate before conception may become less effective later, while increasing it without monitoring may increase adverse effects.
Polytherapy refers to treatment with more than one antiseizure medicine. Several pregnancy registries have found higher rates of major congenital anomalies with combinations than with monotherapy, although the result may partly reflect more severe or treatment-resistant epilepsy. A combination containing valproate is generally more concerning than some combinations without it.
The goal before conception is usually the simplest effective regimen, using one medicine when clinically appropriate and the lowest dose that maintains seizure control. This strategy should be implemented gradually under specialist supervision. Abrupt withdrawal or rapid medication changes can provoke breakthrough seizures, status epilepticus, injury, or loss of driving and occupational safety.
Preconception planning and folate support
Preconception counseling gives clinicians time to review the diagnosis, seizure pattern, medication history, prior pregnancies, coexisting conditions, and the possibility of changing therapy. People who can become pregnant should be given clear information about contraception and pregnancy intentions because organ development begins early.
Folic acid supplementation is commonly recommended before conception and during early pregnancy for people taking antiseizure medication. Higher-dose folic acid is frequently advised in clinical practice, but the ideal dose and its ability to prevent all medication-related malformations remain uncertain. Supplementation should therefore be discussed with a neurologist, obstetrician, or other qualified clinician rather than treated as a complete safeguard.
Medication levels may require monitoring because pregnancy can increase clearance of some drugs, particularly lamotrigine and levetiracetam. The relevant target is usually the individual’s effective pre-pregnancy concentration and clinical response, not a universal number. Symptoms such as increased auras, myoclonic jerks, or breakthrough seizures should be reported promptly.
Prenatal screening and newborn care
A detailed fetal anatomy scan is an important part of care after first-trimester exposure. Depending on the medicine, dose, exposure timing, and family history, clinicians may recommend targeted assessment of the fetal heart, spine, brain, face, kidneys, and growth. Ultrasound can identify many structural abnormalities, but it cannot detect every congenital or developmental condition.
Prenatal testing should be presented as an opportunity for information and planning, not as a guarantee of a normal outcome. A normal scan can be reassuring while still leaving some risks undetectable. Where available, a teratology information service or medication-in-pregnancy registry can provide evidence-based counseling and help document outcomes for future research.
Newborn teams should know about relevant prenatal exposure. Some infants may need observation for withdrawal symptoms, sedation, feeding difficulties, or respiratory problems, depending on the medication and the timing of the last maternal dose. Breastfeeding decisions should be made separately from pregnancy decisions because transfer into milk and infant exposure vary substantially among drugs.
Interpreting evidence for individual care
Much of the evidence comes from pregnancy registries, observational cohorts, and case-control studies rather than randomized trials. Randomly assigning pregnant patients to potentially harmful exposure would be unethical, so researchers must account for confounding factors. People receiving valproate, for example, may differ from those receiving lamotrigine in seizure severity, comorbidities, socioeconomic conditions, and access to care.
Absolute risk is often more useful than a relative-risk statement. If a medication raises the chance of a malformation from a low baseline to a somewhat higher percentage, the decision still requires discussion of the consequences of seizures and the availability of effective alternatives. The same exposure may be reasonable for one patient and unsuitable for another.
Shared decision-making should include the patient’s seizure type, previous response to treatment, reproductive plans, values, and access to specialist monitoring. Neurologists and obstetric clinicians should coordinate rather than issue conflicting advice. A pharmacist, genetic counselor, maternal-fetal medicine specialist, or teratology service may add valuable expertise when the medication history is complicated.
Steps that support safer pregnancy care
- Arrange a medication and seizure review before conception whenever possible.
- Avoid abrupt discontinuation or unsupervised dose changes.
- Discuss whether monotherapy or an alternative medicine can provide reliable seizure control.
- Start folic acid and schedule prenatal screening according to specialist guidance.
- Report pregnancy exposure to an established registry or teratology information service when available.
Pregnancy planning should be treated as ongoing care rather than a single appointment. Medication reconciliation should occur at booking, during periods of changing seizure frequency, and after delivery, when drug clearance and dosing needs can change quickly. Clear written instructions can prevent missed doses and reduce confusion between different clinicians.
Families also benefit from practical safety planning. Adequate sleep, adherence, avoidance of known seizure triggers, and support during periods of vomiting or illness may reduce preventable breakthrough events. Emergency plans should explain when a prolonged seizure or repeated seizures require urgent medical attention.
The evidence surrounding maternal antiseizure therapy continues to evolve as registries collect larger numbers of pregnancies and follow children for longer periods. Reliable counseling depends on considering current research alongside the patient’s medical history, rather than relying on a single headline risk or a generalized list of “safe” and “unsafe” drugs.
If you are planning a pregnancy, are already pregnant, or have concerns about prenatal exposure, arrange a prompt review with your neurologist and obstetric care team. Do not stop an antiepileptic medicine without professional guidance; coordinated planning can help protect seizure control while reducing avoidable fetal risk.
